A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
Not yet recruiting · NCT07615270 · Registry updated 2026-08-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Not yet recruiting | Early phase 1 | 2026-08-21 | NCT07615270 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Stanford University | 620 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Stanford University | Palo Alto | United States | 51 |